Detecting a treatment-biomarker interaction, which is a task better suited for large sample sizes, in a phase II trial, which has a small sample size, is challenging. In this paper, we investigate how two plausibly available sources of historical data may contain partial information to help estimate the treatmentbiomarker interaction parameter in a randomized phase II study. The parameter is not identified in either historical dataset alone; nonetheless, both can provide some information about the parameter and, consequently, increase the precision of its estimate. To illustrate the potential for gains in efficiency and implications for the design of the study, we consider Gaussian outcomes and biomarker data and calculate the asymptotic variance using the expected Fisher information matrix. We quantify the gain in efficiency both through a numerical study and, in a simplified setting, insights derived from an algebraic development of the problem. We find that a non-negligible gain in precision is possible, even if the historical and prospective data do not arise from identical underlying models.
this prior belief regarding the existence of interactions could be true. Such information is crucial to help inform the design of the next study to further evaluate the treatment.
In this paper we consider the situation of a modestly sized, prospective randomized phase II trial, which is not intended to be definitive but rather informative about whether to proceed to a more definitive phase III trial. The possible future phase III trial might be restricted to subjects with high values of the biomarker, or it may be an all-comers trial. The size, expense, and likelihood of reaching a sound conclusion from the phase III trial may depend on the selected design. Thus learning as much information as possible from the phase II trial about how the treatment effect varies by the level of the biomarker is of great importance. For trial design, and statistical models in general, it is well-known that larger sample sizes are needed to test and estimate interactions than are needed to test and estimate main effects. 6 Because the sample size of the phase II trial is already modest, any means of increasing the precision of the estimate of the interaction would be very useful. Motivated by this, we posit that historical data can increase the precision of estimates of treatmentbiomarker interactions. Although such data by itself does not typically provide direct information about the interaction parameter, it is plausible that, when combined with the data from the prospective phase II trial, it could lead to improved efficiency in the estimation of the treatment-biomarker interaction.
The motivation for this research comes from a phase II study currently ongoing at the University of Michigan. In the study, which has several unique features that we will not consider, castrationresistant prostate cancer patients are evaluated for ETS transcription factors ERG and ETV1 in their biopsied, metastatic lesion. Overexpression of these biomarkers represents an ETS gene fusion in the prostate tumor, which is driven by an androgen-sensitive promoter. 7 Additionally, ETS-mediated oncogenic features such as metastasis and tumor growth depend on PARP1, thus the PARP1inhibitor ABT-888 can specifically target ETS-positive prostate cancers. 8 The trial design is a stratified randomized phase II with a planned sample size of 148 evaluable patients and two treatment arms: abiraterone with prednisone (A þ P) versus abiraterone with prednisone and ABT-888 (A þ P þ B). The trial will evaluate the role of ETS gene fusion as a predictive biomarker comparing A þ P to A þ P þ B in this patient population. Two hypothetical sources of additional data that would help inform about the interaction are (1) data from subjects who all received A þ P and have measurements of the ETS gene fusion or (2) trial data from subjects to whom either A þ P or A þ P þ B were given but for which ETS gene fusion status is not known. This second study may either be observational or a randomized trial.
In this paper, we consider a general statistical framework for a problem of this type and undertake an evaluation of the potential for such auxiliary data to help in the analysis of the data from the phase II study. In this general framework, Thall and Simon 9 investigate how to use historical control data to improve estimates of the main effect of treatment. More recently, Neuenschwander et al. 10 discuss how to incorporate historical estimates of treatment effects and characterize their contribution through the calculation of an effective historical sample size. However, Cuffe 11 shows that incorporating historical control data for estimating treatment effects can decrease power if the historical and prospective data are too incompatible, which may not be known until after the prospective trial is complete. In the context of augmenting human data with that from animal studies, DuMouchel and Harris 12 suggest to ascertain multiple sources, so as to minimize sensitivity to any single historical dataset. We will focus on the efficiency of estimation for the interaction term, which will be evaluated by consideration of the expected Fisher information matrix. For our purposes, to illustrate the potential efficiency gain, we restrict our attention to the case where both the response variable and the biomarker are continuous, and the data can be described by a linear model with Gaussian errors. The research has implications for both the analysis and the design of the planned phase II trial. The analysis question is how much gain in efficiency is possible from the auxiliary data. There are two possible design issues, one being how much auxiliary data should be acquired or gathered and the other whether it is useful to have an unequal randomization between treatment arms in the prospective trial. In the remainder of the paper, we introduce notation and the models for the problem (Section 2), interpret the results of our numeric and analytic study of the problem (Sections 3 and 4), and close with a brief discussion (Section 5). The algebraic details of our work are primarily in the Web Appendix.
Notation and Models
Let Y be the outcome measure. A binary variable T2fÀ1/2,1/2} indicates the new drug or treatment, with T ¼ À1/2 for those who receive the standard treatment. The other covariates in the model are W ¼ fW 1 , W 2 , . . . , W q g > 2 R q , assumed to be a length-q vector of commonly measured prognostic variables, and V 2 R, which is the biomarker. The biomarker is chosen so that patients with higher values of V are expected to be more responsive to the new treatment. In the simplest case of a continuous Y, the outcome model may be given by
Our primary goal in this paper is to determine if V is predictive, meaning that a patient's measure of V determines in part the extent the treatment T affects Y. Algebraically, this is true if 6 ¼ 0. In contrast, our focus is not in determining whether V is prognostic, which means that typical values of the outcome Y depend on V for patients treated under the standard of care, i.e. when T ¼ À1/2. The biomarker is prognostic if V À =2 6 ¼ 0. Clearly, V may be both prognostic and predictive, but inference on is of primary interest.
Group 1: Prospective randomized clinical trial (RCT). We call the primary, small prospective phase II study group 1 and assume it has n 1 observations. The treatment T may take on both values in this group. Because the data in group 1 come from a RCT, T is assumed to be independent of both V and W.
Group 2:
Historical data under standard of care. In group 2, T ¼ À1/2 for all observations, corresponding to a set of patients treated under the standard of care, and the biomarker V is measured. We will call these data, containing n 2 observations, group 2. By itself, group 2 only provides information about the quantity V -/2, i.e. whether or not the biomarker is prognostic, and is not identified because T does not vary in this group. However, as we will show, even by helping to inform the quantity V -/2, group 2 may still provide a gain in efficiency for estimating .
Group 3:
Historical data that is missing biomarker information. In these data (group 3), T varies, as with group 1, but the biomarker V is unmeasured. These may be patient data from earlier-phase studies of the treatment of interest, either observational or a randomized study, before the biomarker V was identified or in which it was not measured. It is reasonable to assume that the distribution of T is conditionally independent of (the unobserved) V given W. This is trivially satisfied if group 3 arises from an RCT. However, even if group 3 comes from an observational study, so that the distribution of T depends on the prognostic variables W, conditional independence may be assumed because V was not measured or not known. The assumption is critical because it differentiates this scenario from a more problematic retrospective validation of purely observational data, in which T and V may be highly correlated. 13 In practice, conditional independence will not hold exactly; however, if W is sufficiently rich, assuming so will be a good approximation. Depending on the underlying model for V or VjW, by itself, group 3 will typically only provide information on expressions containing both and the remaining elements of b, and alone is not identified. However, as with group 2, group 3 may contribute a gain in efficiency for estimating when combined with group 1.
We will quantify this efficiency gain in estimating from the inclusion of groups 2 or 3 through a numerical evaluation of Fisher information matrices. The assumed biomarker and treatment models are, respectively
where expitfxg ¼ ½1 þ expðÀxÞ À1 . Model (3) does not apply to group 2, because T does not vary in that group. We also assume that a ¼ 0 q in group 1, because it is a randomized trial. If group 3 corresponds to data from an observational study, then a 6 ¼ 0 q . When V is missing, as in group 3, the marginal outcome model can be determined by mixing over the original outcome model (1) and the biomarker model (2), leading to
The variance of YjT, W depends on the value of the treatment T. Under these models, then, four functions of the parameters contain , through which group 3 contributes its relevant information:
Remark 1: Although models (1)-(3) are written so that all parameters are shared between the three groups, we will weaken this assumption in our numerical study. The intercepts 0 and 0 may vary between groups, which is important because it allows for the populations to differ in ways that may not be explained by W.
Remark 2: It is not necessary to write an explicit model for W, because it is fully observed in all groups. For ease of notation, we denote the first two moments of W as E½W and E½WW > but do not require that these be equal between groups.
Numerical study of efficiency gains
In this section, we assess, through a numerical study, the benefit to the analysis of group 1, assumed to be RCT data, from adding either the group 2 or group 3 data. To do this, we estimate the asymptotic variance of the interaction parameter by numerically calculating and inverting the expected Fisher information matrices of the parameters from models (1) and (2) and recording the resulting entry corresponding to . The expected Fisher information matrices for one observation from groups 1, 2, or 3 are respectively denoted as I 1 , I 2 , or I 3 and are derived in Appendices A1-A3
where, in
Reading down the diagonal of each matrix, the elements correspond to 0 , T , b W , V , , 2 , 0 , c, and 2 , and so the fifth row/column, corresponding to , is of primary interest. Compared to I 1 or I 2 , I 3 contains additional non-zero off-diagonal elements, which may depend on the values of V or , because it is required to marginalize over the missing biomarker measurements V, which are fully observed in groups 1 and 2. For each group, given a set of parameter values, we independently sample 100,000 draws of W $ Nðl, AE W Þ, TjW (for groups 1 and 3), and VjW (for groups 1 and 2), and calculate the average values of I 1 , I 2 , and I 3 . Given these estimates of typical information matrices, define the following measures of relative efficiency for estimating , given some non-negative number k:
For an arbitrary sample size n 1 , RE 2 (k), RE 3 (k), RE 23 (k), and RE max (k) are, respectively, the variance of from analyzing (1) group 1 containing n 1 observations and group 2 containing kn 1 observations, (2) group 1 containing n 1 observations and group 3 containing kn 1 observations, (3) group 1 containing n 1 observations, group 2 containing 0.5kn 1 observations, and group 3 containing 0.5kn 1 observations, and (4) group 1 containing n 1 (1 þ k) observations, relative to the variance of from analyzing group 1 alone, containing n 1 observations. The quantity k is the sample size ratio of the added data versus the original group 1 data, and the value of n 1 is arbitrary. The final metric, RE max (k), may be considered the ideal efficiency gain, in which the additional data are most informative for estimating because group 1 increases in size. As mentioned, group 1 is supposed to correspond to RCT data, meaning that a ¼ 0 q throughout. We vary a in group 3 to represent RCT data (¼ 0 q ) or observational data (6 ¼ 0 q ).
We now discuss the parameter values considered, which are summarized in Table 1 .
YjX [Model (1)] Because (1) is a Gaussian-linear model, the information matrices from groups 1 and 2 do not change with any elements of b, and the error variance 2 acts only as a multiplicative Table 1 . Summary of parameter values in numerical studies. The parameter varies for group 3 only; for group 1, it is fixed at a ¼ 0 q : R 2 is used to determine by solving
The marginal expectations E[V] and E[T] respectively induce values for g 0 and a 0 .
Model
Parameter Values used
Statistical Methods in Medical Research 25 (6) scalar. However, the information matrix from group 3, which requires marginalization over V, does depend on V , , and 2 (Appendix A3). We consider three sets of values for V and , f V , g 2 ff0, 1g, f1= ffiffi ffi 5 p , 2= ffiffi ffi 5 p g, f2= ffiffi ffi 5 p , 1= ffiffi ffi 5 p gg. Graphical depictions of these three choices are given in Figure 1 . For a fixed fraction of explained variance R 2 2f0.1,0.3,0.5}, we determine 2 by solving
Appendix A4 has details on this calculation. The parameters T and b W are required only for calculating 2 ; we use T ¼ 0 and
. Finally, we allow the intercept 0 to differ between groups, meaning that each group's information matrix has a distinct row and column for 0 , and no group contributes information regarding another group's intercept. However, because we are focusing only on efficiency, the information contribution remains the same for an arbitrary set of three intercepts and no actual values need to be chosen.
VjW [Model (2)] For the biomarker model, we use c ¼ ðq À1=2 Þ1 q , so that c > c ¼ 1. We chose 0 so that, for a given E½W (see following paragraph) and c, we have E½V ¼ 0 þ c > E½W ¼ 0. As already noted, we assume that 0 , like 0 , varies between groups, so that each group's information matrix contains a distinct row and column for 0 . To determine 2 , we solved
3)] and model for W For group 1, we assume that a ¼ 0 q and 0 ¼ 0, corresponding to a RCT with equal randomization probabilities. For group 2, no model for T is required because T is fixed at À1/2. For group 3, we considered a 2 f0 q , ð2q À1=2 Þ1 q g but still chose 0 so that E½T ¼ E½expitf 0 þ a > Wg À 0:5 ¼ 0. We drew W from a multivariate normal distribution with E½W l ¼ 0 q and Var½W AE W ¼ diagf1, 1, . . . , 1g.
Graphical depictions of how each RE measure changes with k for f V , g ¼ f1= ffiffi ffi 5 p , 2= ffiffi ffi 5 p g are given in Figure 2 The typical initial drop in RE 2 (k) is steep, suggesting that even a small amount of data from group 2 is helpful. However, there are diminishing gains from increasingly large sample sizes in group 2, and the curves for group 2 eventually plateau at some positive asymptote. Under this model configuration, the asymptote is lim k!1 RE 2 ðkÞ ¼ 0:5. Section 4 discusses this in more detail. The efficiency gains from a small amount of group 3 are less noticeable. Empirically, there is also an asymptote for possible efficiency gains from group 3 (not shown). However, the height of the 
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Statistical Methods in Medical Research 25 (6) asymptote changes and may be smaller than 0.5, as in the right-most column of Figures 2 and 3 . When a ¼ 0 q (Figure 2 ), RE 3 (k) is smaller than when a 6 ¼ 0 q (Figure 3) , meaning, when the group 3 data are from an observational study, they are generally less informative for estimating than when they come from an RCT. The figures also contain RE 23 (k), which is the relative efficiency from adding 0.5kn 1 observations from each of groups 2 and 3. In all cases, at around k ¼ 1, RE 23 (k) is smaller than either RE 2 (k) or RE 3 (k), suggesting an apparent synergy from the joint addition of data from both groups 2 and 3. Also, in the cases we considered, the asymptote is empirically always nearly zero, meaning that, with enough data, adding equal numbers of observations from both groups can match the ideal scenario of having an equivalently-sized group 1. In other words, adding some data from both groups would seem most preferred. We reiterate that these results are for the case when 0 and 0 are assumed to differ between groups. These results are also invariant to the true value(s) of 0 , because it does not appear in the information matrix, and numerical studies (not shown) suggest that these are invariant to the true values of l and 0 , even when they vary between groups. Intuitively, then, these parameters are not primarily responsible for the efficiency gain in estimating .
Combining groups 1 and 2
In this section, we analytically assess the potential contribution from group 2 toward inference on , with the goal of optimally randomizing the group 1 patients. Here, we assume it is known that 0 ¼ 0 and E½W ¼ 0 q for both groups. The matrix ð1=n 1 ÞðI 1 þ kI 2 Þ À1 , with I 1 and I 2 as in (5) and (6), is the large-sample covariance matrix of the parameters, where k ¼ n 2 /n 1 is the sample size ratio as in Section 3. Some algebra (Appendix A5) gives that the large-sample variance of is vð T , n 1 , kÞ ð1=n 1 ÞfðI 1 þ kI 2 Þ À1 g ½5,5
From this, only the last expression contains k, and so the variance reduction from adding group 2 does not depend on the values of any model parameters except T . We can use (8) to calculate the maximum possible efficiency gain from adding group 2 lim k!1 vð T , n 1 , kÞ vð T , n 1 , 0Þ
¼ lim
when T ¼ 0, the addition of group 2 can reduce the variance of by no more than 1/2, compared to using group 1 alone; this is the asymptote for RE 2 (k) in Figures 2 and 3 . A larger variance reduction may be possible as T increases toward 1/2. For designing a trial that will generate data corresponding to group 1, we can also use (8) to choose how to optimally randomize the n 1 individuals, given n 2 , so that we have the largest possible efficiency for estimating . That is, choose T to minimize vð T , n 1 , kÞ @ log vð T , n 1 , kÞ
A consequence of this is that, if k ! 1, equivalently n 2 ! n 1 , then the asymptotic variance of is minimized by assigning all patients in group 1 to the treatment arm, i.e. T ¼ 1/2. In other words, when group 2 is large and precision of is of primary importance, the prospective phase II trial should be a single-arm trial. Although the result assumes that the generating model for the outcome is identical between groups, which is why randomization within group 1 is often recommended, 14 this may be relaxed somewhat. Namely, the expression for vð T , n 1 , n 2 Þ in (8) is free of the intercept and treatment effect, respectively 0 and T . Also, 0 and T are independent of. Therefore, it is possible to parameterize (1) so that 0 and/or T differ between groups 1 and 2 (subject to constraints on identifiability) while still being able to show that opt T in (9) remains the same.
An analogous result of finding an optimal T when combining groups 1 and 3 would also be desirable, but the integration over the missing measurements of V adds complexity to the matrix I 1 þ kI 3 , and a closed-form solution to its inverse, while theoretically possible, does not lend itself to the same intuition as above.
Discussion
Phase II trials are, by definition, of a smaller scope. However, it is not uncommon for a primary or secondary aim of such a trial to be identifying a particular biomarker-treatment interaction, for which large sample sizes are necessary for efficient estimation. Given this, it is important to use as much available historical data as possible. Through some asymptotic calculations for a specific model, we have demonstrated the potential gain in efficiency in estimating a biomarker-treatment interaction by using auxiliary data. The exact numerical results are dependent on the specifics of the model, such as continuous outcome and biomarker variables and Gaussian distributions. While we have not investigated it, we hypothesize that the findings would be qualitatively similar for other data types and distributions. We will investigate this in our future work.
From a design perspective, in Section 4, we established conditions under which, if sufficiently many observations from group 2 are available, assigning more, or even all, group 1 patients to the treatment may increase the resulting precision of relative to equal-armed randomization. A critical assumption here was that the generating models underlying each group are similar, although they need not be identical: the intercept and main effect for treatment may differ in the outcome model between groups. However, there are other reasons why it is important to have equal randomization between treatment arms, including differences in the models beyond those considered above 15 or study aims that are of a higher priority than identifying biomarker-treatment interactions. Or, to balance the desire for efficiency gains with possible model discordance, a biased randomization design could assign most, but not all, patients to the experimental treatment arm, so that contemporaneous information about the control arm is available.
The most important result from this study is in Section 3 and suggests that more auxiliary data, from either group 2 or group 3, is always better. In every parameterization we considered, including three different types of interaction that could be encountered in practice (Figures 2 and 3 and A1-A4 in the Appendix), there was an initial steep drop from adding group 2 data, with considerable gains in efficiency possible up to k ¼ 1, that is, up to a doubling of the sample size of the original group 1 data. The efficiency gains become marginal as more historical data from a single group are used. If observations from both groups were available, then a synergistic effect was evident, and greater efficiency gains were observed. This synergy is a result of each group contributing different information about the outcome and biomarker models. A practical recommendation when studying treatment-biomarker interactions in phase II trials is therefore to critically assess the types of historical data available to see how they might be incorporated into the analysis of the phase II trial.
While we allow the intercepts in the outcome and biomarker models, respectively, equations (1) and (2) , and the distribution of W to vary between groups, we do require that the parameters in the outcome model related to the biomarker, namely V and , be the same between groups. A violation to this assumption of the models between groups being ''similar enough'' may change the results of our analysis, in particular the initial steep drop in variance, but the impact from groups 2 and 3 could be down-weighted, for example, through a Bayesian analysis with a commensurate or power prior. 16, 17 That is, apart from using the likelihood, we have not prescribed a particular analysis method, and, by incorporating historical data into a prior, the Bayesian approach may be ideal for managing its contribution to the analysis.
Beyond issues related to differences in models, although a biomarker-treatment interaction comprises a fundamental aspect in our statistical formulation, detection of a linear statistical interaction is neither necessary nor sufficient for determining whether a biomarker is informative for patient-specific treatment assignments. With respect to necessity, there are other ways to characterize a predictive biomarker, an example being identifying subgroups defined by regions of the covariate space in which the treatment is more likely to be effective. [18] [19] [20] In contrast to a single biomarker V, methods for subgroup identification are better-suited for more complex scenarios in which the treatment effect is expected to vary with respect to several biomarkers and/or covariates. By focusing on the single biomarker situation, which is not uncommon, we are able to better quantify the information gain from the historical data. With respect to sufficiency, two biomarkers may have the same interaction coefficient but differ in their clinical utility 21, 22 ; in the framework of the models considered in this paper, clinical utility increases as increases in magnitude relative to V . These references, however, do not consider the addition of auxiliary data, and this article is a ''proof-ofconcept'' paper supporting the contention that if auxiliary data are available, they may aid in the design and subsequent analysis of the proposed randomized phase II study.
